Picture of Tectonic Therapeutic logo

TECX — Tectonic Therapeutic News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousSmall CapNeutral

Tectonic Therapeutic Inc expected to post a loss of $1.50 a share - Earnings Preview

* Tectonic Therapeutic Inc  TECX.OQ   TECX.O  is expected
to show
no change in quarterly revenue when it reports  results on
August 8 (estimated) for the period ending January 1 0001
    * 
    * ​LSEG's mean analyst estimate for Tectonic Therapeutic Inc
is
for a loss of $1.50 per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Tectonic
Therapeutic Inc is $62.50​, above​ its last closing price
of $16.91. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Mar. 31 2024  -4.32       -4.32      -1.80     Beat    58.3
 Dec. 31 2024  -4.95       -4.04      -2.40     Beat    40.6
 Sep. 30 2023  -3.34       -3.40      -5.28     Missed  -55.3​
 Jan. 1 0001   -2.48       -0.90      -4.44     Missed  -395
 ​​Mar.        -6.50       -6.54      -6.84     Missed  -4.6
 31 2023                                                
 Jan. 1 0001               -5.91      -6.84     Missed  -15.7​
 Sep. 30 2022  -6.82       -6.60      -6.24     Beat    5.5
 Jun. 30 2022  -7.07       -6.87      -7.68     Missed  -11.8
 This summary was machine generated August 7 at 02:01 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)

Recent news on Tectonic Therapeutic

See all news